Form 4: Rocket Pharmaceuticals Executive Sells Shares to Cover Tax Obligations

Kinnari Patel, President, Head of R&D and Chief Operating Officer of Rocket Pharmaceuticals, sold 1,409 shares of common stock to cover tax obligations related to vesting Restricted Stock Units.

Summary

• Kinnari Patel, an executive at Rocket Pharmaceuticals, sold 1,409 shares of common stock on May 16, 2025, at a price of $6.528 per share.
• The sale was to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
• Following the transaction, Patel directly owns 442,694 shares of Rocket Pharmaceuticals common stock.
• Patel also indirectly owns 26,774 shares through her spouse and 104,927 shares through Adaptive Technology LLC, a limited liability company owned and managed by her husband.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing a stock sale for tax purposes, indicating a neutral sentiment.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This sale appears to be routine, covering tax obligations related to vested equity.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates

Keywords

Rocket Pharmaceuticals, Kinnari Patel, stock sale, Form 4, insider trading, RSUs, tax obligations, Adaptive Technology LLC